TRPV1 and obesity due to melanocortin 4 receptor deficiency: Thirdly, the long-terms effects of TRPV1 antagonist administration need to be investigated both for beneficial actions (for example, reduced CVD risk, including obesity-induced hypertension [50]) and adverse effects such as impaired noxious heat perception [31,32]).